Bitopertin
- Generic Name
- Bitopertin
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20F7N3O4S
- CAS Number
- 845614-11-1
- Unique Ingredient Identifier
- Q8L6AN59YY
- Background
Bitopertin has been used in trials studying the treatment of Schizophrenia and Obsessive-Compulsive Disorder.
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 301
- Registration Number
- NCT01234779
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 624
- Registration Number
- NCT01192906
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 625
- Registration Number
- NCT01192880
- Locations
- πΊπΈ
Synergy Clinical Research of Escondido, Escondido, California, United States
πΊπΈExcell Research, Oceanside, California, United States
πΊπΈBehavioral Clinical Research Inc., Lauderhill, Florida, United States
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 629
- Registration Number
- NCT01192867
- Locations
- πΊπΈ
Family Psychiatry of the Woodlands P.A., The Woodlands, Texas, United States
πΊπΈCNRI - Los Angeles, LLC, Pico Rivera, California, United States
πΊπΈPillar Clinical Research LLC, Dallas, Texas, United States
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT01116830
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 323
- Registration Number
- NCT00616798
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath